...
首页> 外文期刊>The journal of obstetrics and gynaecology research >Plasma CADM1 promoter hypermethylation and D-dimer as novel metastasis predictors of cervical cancer
【24h】

Plasma CADM1 promoter hypermethylation and D-dimer as novel metastasis predictors of cervical cancer

机译:血浆CADM1启动子高甲基化和D-二聚体作为宫颈癌的新型转移预测因子

获取原文
获取原文并翻译 | 示例

摘要

Aim Cervical cancer (CC) is the fourth malignant tumor in women worldwide. The metastasis is still the major reason for the treatment failures of most CC patients. Cell adhesion molecule 1 (CADM1) promoter methylation and plasma D-dimer levels have been reported to be increased in many types of cancers. The purpose of this study was to investigate the value of combinatorial assay of plasma CADM1 promoter hypermethylation and D-dimer as a metastasis marker in CC. Methods Two hundred and ninety-two patients with newly diagnosed cervical diseases and 70 healthy women were enrolled. A validation set comprised 36 Stage I CC patients and followed for 3 years. Plasma CADM1 promoter methylation and D-dimer levels were detected. Results The total coincidence rate of CADM1 promoter methylation status was 93.3% between 45 pair-matched tissue and plasma samples. Plasma CADM1 methylation levels in CC patients were higher than other benign disease groups (P = 0.000). Plasma CADM1 methylation levels had statistically differences between CC patients with and without lymph node metastasis (P = 0.049) or in CC patients with and without distant metastasis (P = 0.000). Similarly, plasma D-dimer levels in CC patients were higher than other benign disease groups (P < 0.05). D-dimer levels were only statistically different between CC patients with and without distant metastasis (P = 0.003). Combined assay of the two parameters for metastasis prediction has high sensitivity (80.4%) and specificity (90.5%). Conclusion Combinatorial assay of plasma CADM1 methylation and D-dimer is a promising metastasis marker in cervical cancer.
机译:目标宫颈癌(CC)是全球妇女的第四个恶性肿瘤。转移仍然是大多数CC患者治疗失败的主要原因。据报道,细胞粘附分子1(CADM1)启动子甲基化和血浆D-二聚体水平在许多类型的癌症中增加。本研究的目的是研究血浆CADM1启动子高甲基化和D-二聚体的组合测定的价值作为CC中的转移标记。方法注册了二百九二九二患有新诊断的宫颈疾病和70名健康妇女的患者。验证组包括36阶段I CC患者,然后进行3年。检测血浆CADM1启动子甲基化和D-二聚体水平。结果CADM1启动子甲基化状态的总重合率为45对匹配组织和等离子体样品的93.3%。 CC患者的血浆CADM1甲基化水平高于其他良性疾病群(P = 0.000)。血浆CADM1甲基化水平在CC患者与没有淋巴结转移(P = 0.049)或具有和没有远处转移的CC患者(P = 0.000)之间的统计学上差异。类似地,CC患者的血浆D-二聚体水平高于其他良性疾病组(P <0.05)。 D-二聚体水平仅在具有和没有远离转移的CC患者之间统计学不同(P = 0.003)。转移预测的两个参数的组合测定具有高灵敏度(80.4%)和特异性(90.5%)。结论血浆CADM1甲基化和D-二聚体的组合测定是宫颈癌中有前途的转移标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号